Susceptibility to severe COVID-19 in patients with MyD88 or IRAK-4 deficiency. (A and B) Severity (A) and OR (B) of SARS-CoV-2 infection in MyD88/IRAK-4–deficient patients relative to the age-matched controls from the NC3 cohort infected with the same viral variants. *, P < 0.001. (C and D) Severity (C) and OR (D) of SARS-CoV-2 infection in heterozygous relatives of MyD88- or IRAK-4–deficient patients relative to the Spanish general population between the ages of 20 and 49 yr after the first wave (April 2020).